Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,194.14 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.13% of total voting rights).
- Shares in Issue: 5,191,239,013 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 1,000,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158, while the number of shares in issue remains 5,191,239,013.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure.
Investor Verification Points
- Verify the total cost of the repurchase (1,000,000 shares at 1,194.14 pence) against the Company's cash position in other filings.
- Confirm the updated Treasury share count of 474,194,158 for voting rights calculations.
- Review the Financial Services Authority's Disclosure and Transparency Rules to understand notification thresholds based on the 5,191,239,013 shares in issue.